恩替卡韦联合双歧杆菌三联活菌胶囊治疗慢性乙型肝炎后肝硬化疗效观察  

Efficacy Observation of Entecavir Combined with Bifidobacterium Triple Viable Capsules in the Treatment of Patients with Cirrhosis Induced by Chronic Hepatitis B

作　　者：吕玉立[1] 陆浩炎[1] 李舒丹[2] 

机构地区：[1]杭州市第一人民医院药学部,杭州310006 [2]杭州市第一人民医院消化科,杭州310006

出　　处：《中国药师》2017年第4期677-679,共3页China Pharmacist

摘　　要：目的:观察恩替卡韦联合双歧杆菌三联活菌胶囊治疗慢性乙型肝炎后肝硬化患者临床疗效和安全性。方法:慢性乙型肝炎后肝硬化患者86例随机分为观察组43例与对照组43例。对照组给予恩替卡韦胶囊治疗,观察组在对照组基础上加用双歧杆菌三联活菌胶囊。两组疗程均为3个月。比较两组疗效,治疗前后胆红素(TBi L)、AST、ALT等肝功能指标和透明质酸(HA)、Ⅲ型前胶原(PCⅢ)及层黏蛋白(LN)等肝纤维化指标变化,及药品不良反应发生情况。结果:观察组治疗总有效率明显高于对照组(P<0.05)。治疗后,两组患者TBi L、AST、ALT水平,以及HA、PCⅢ、LN水平均较前明显降低(P<0.05);且观察组患者上述指标水平显著低于对照组(P<0.05)。两组均未见药品不良反应发生。结论:恩替卡韦联合双歧杆菌三联活菌胶囊治疗慢性乙型肝炎后肝硬化疗效显著,可改善患者肝功能和肝纤维化,且安全性好。Objective： To investigate the clinical efficacy and safety of entecavir combined with triple viable bifidobacterium capsules in the treatment of patients with cirrhosis induced by chronic hepatitis B. Methods： Totally 86 chronic hepatitis B patients with cirrhosis were randomly divided into the observation group and the control group with 43 ones in each. Thecontrol group was given entecavir treatment, and the observation group was treated with triple viable bifidobacterium capsules additionally. The treatment course was three months. The effect of treatment, changes of liver function （ TBiL, AST, ALT, etc. ）, liver fibrosis level （ HA, PC Ⅲ, LN, etc. ） and adverse events were compared between the groups before and after the treatment. Results： The total effective rate of the observation group was higher than that of the control group （ P 〈 0. 05 ） ; the levels of TBiL, AST and ALT decreased in both groups after the treat- ment （P 〈 0.05 ）, and those in the observation group were tower than those in the control group （ P 〈 0.05 ） ; the levels of HA, PC III and LN decreased in the two groups after the treatment （ P 〈 0.05 ）, and those in the observation group were lower than those in the control group （p 〈 0.05 ） ; there were no significant adverse drug reactions in both groups during the treatment course. Conclusion： Entecavir combined with triple viable bifidobacterium capsules in the treatment of patients with cirrhosis induced by chronic hepatitis B exhibits significant clinical efficacy, which can improve liver function and liver fibrosis with promising safety and without significant ad- verse reactions.

关 键 词：双歧杆菌三联活菌胶囊 恩替卡韦 慢性乙型肝炎 肝硬化 

分 类 号：R512.62[医药卫生—内科学]